Minerva Neurosciences (NERV) Short term Debt (2013 - 2014)
Minerva Neurosciences (NERV) reported Short term Debt of $1.4 million for Q2 2014, up 13600.75% quarter-over-quarter from $10093.0 in Q4 2013.
Minerva Neurosciences (NERV) Short term Debt (2013 - 2014) Analysis & Trends
Minerva Neurosciences has reported Short term Debt for 2 years, with the latest figure at $1.4 million in Q2 2014.
- For the quarter ending Q2 2014, Short term Debt changed N/A year-over-year to $1.4 million; the trailing twelve-month figure through Jun 2014 stood at $1.4 million (changed N/A YoY), and the FY2013 full-year result was $10093.0, changed N/A from the prior year.
- Short term Debt for Q2 2014 stood at $1.4 million, up from $10093.0 in the prior quarter.
- The five-year high for Short term Debt was $1.4 million in Q2 2014, with the low at $10093.0 in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Minerva Neurosciences | 197.55 Mn | 197.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2014 | 1.38 Mn |
| Dec 31, 2013 | 10,093.00 |